Affirmed Therapeutics BV (NASDAQ:AFMD) was up 1.9% during trading on Monday . The company traded as high as $2.78 and last traded at $2.67, with a volume of 52,117 shares traded. The stock had previously closed at $2.62.

A number of equities research analysts have commented on AFMD shares. BMO Capital Markets started coverage on shares of Affirmed Therapeutics BV in a research report on Monday, April 11th. They issued an “outperform” rating and a $7.00 target price for the company. Jefferies Group dropped their price target on shares of Affirmed Therapeutics BV from $5.00 to $4.00 and set a “hold” rating on the stock in a research note on Thursday, May 19th. Wells Fargo & Co. reiterated a “buy” rating on shares of Affirmed Therapeutics BV in a research note on Wednesday, May 18th. Finally, Leerink Swann cut shares of Affirmed Therapeutics BV from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 19th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $9.46.

The firm’s 50-day moving average price is $2.84 and its 200-day moving average price is $3.49. The stock’s market cap is $91.73 million.

Affirmed Therapeutics BV (NASDAQ:AFMD) last posted its earnings results on Wednesday, May 18th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.17) by $0.08. The company had revenue of $1.90 million for the quarter, compared to the consensus estimate of $1.88 million. Affirmed Therapeutics BV’s revenue was down 24.0% on a year-over-year basis. On average, equities analysts expect that Affirmed Therapeutics BV will post ($1.06) earnings per share for the current year.

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.